Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited announced the quotation of 788,786 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 1, 2025. This move reflects the company’s strategic efforts to enhance its market presence and liquidity, potentially impacting its financial standing and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies, vaccines, and other specialty biopharmaceutical products, serving a global market with a strong emphasis on research and development.
Average Trading Volume: 997,842
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8B
See more data about CSL stock on TipRanks’ Stock Analysis page.